ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

POLB Poolbeg Pharma Plc

14.10
-0.80 (-5.37%)
Last Updated: 09:26:45
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Poolbeg Pharma Plc POLB London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.80 -5.37% 14.10 09:26:45
Open Price Low Price High Price Close Price Previous Close
14.85 14.10 15.00 14.90
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Poolbeg Pharma POLB Dividends History

No dividends issued between 08 May 2014 and 08 May 2024

Top Dividend Posts

Top Posts
Posted at 07/5/2024 22:47 by elrico
Sicko, It's unjust to judge others by your own standards. I consistently reveal my sale/top slice a minimum of two trading days in advance if I possess a stated position. Additionally, not everyone can dedicate hundreds of hours each month; some have demanding careers, families, etc. Nevertheless, I do concur that whenever feasible, investors ought to DTOR, such as reviewing independent analyses. You might label these individuals as "cheerleaders" to fit your narrative. Relying on your analyses could have been risky with HVO and POLB, yet one thing is certain, you have been consistently inaccurate.

I recall you singing the pump & dump song when POLB share price was c6p. Had anyone been put off by your constant trashing, they would have missed out on healthy gains. I do hope you are pleased with yourself.

Instead of just highlighting investors' losses, why not provide some balance by sharing your own? As flawless as you may seem compared to Buffet and Munger, I'm fairly certain you've also had your fair share of failed investments. I know I have over the past 30+ years.

Play nice!
Posted at 07/5/2024 12:17 by sikhthetech
Mucho,

Why does Nexn (ex-trmr/rthm/blnx) go quiet when Polb/HVO is busy and vice versa?

Do you think it's because it's difficult for the blnx pump and dump gang with their multiple ids to post on both HVO/Polb and Nexn at the same time?????
;-)
Posted at 01/5/2024 07:28 by burtond1
Great news #POLB We received the fully granted patent from the US Patent Office for our Immunomodulator II patent application.The claims cover the treatment & prevention of cytokine storm after an immune response has been triggered - in any disease indicationhttps://www.londonstockexchange.com/news-article/POLB/significant-polb-001-patent-granted-in-usa/16448784
Posted at 30/4/2024 08:15 by burtond1
POLB CEO is joined by the CEO of Silk Road Therapeutics on @Proactive_UK:? Silk Road Therapeutics option agreement? Behçet's Disease? Development of tPTX? Commercial Attraction?? Overview of #POLB full year resultshttps://www.youtube.com/watch?v=MOTQwbvmIuQ&t
Posted at 20/3/2024 07:56 by burtond1
??????????? RNS this for @PoolbegPharma Notice of Allowance for Significant POLB 001 Patent in United States"...I am excited by the potential of POLB 001 to positively impact global health..."#POLB CEO Jeremy Skillingtonhttps://www.londonstockexchange.com/news-article/POLB/polb-001-us-patent-update/16385543
Posted at 15/2/2024 11:07 by 1gw
parsons4 - well if we take CF's relatively recent linkedin post at face value (and I know some don't) about aiming to complete the IPO of POLB on Nasdaq later this year then I can understand his desire to get the share price up ahead of setting the price for that.



If I were then to look at even more recent discussion of acquiring and commercialising rare/orphan disease drugs, I might start to think that there could be a plan to acquire or reverse in to an existing Nasdaq-quoted company that was low on cash but had some promising approved or late phase drugs, particularly if those drugs were in the oncology space that would fit with trials of POLB001 for immunotherapy-induced CRS. I could see a story to justify raising funds around progressing POLB001 in parallel with the rollout of these drugs.

Whether IPO'ing directly as POLB, or raising cash following, or as part of, an acquisition/reverse, a high shareprice would be a lot more useful than a low shareprice in terms of minimising the dilution of existing shareholders.
Posted at 12/2/2024 09:16 by burtond1
Massive opportunity this for #POLB https://www.londonstockexchange.com/news-article/POLB/market-opportunity-for-polb-001-for-crs/16327313Research conducted on behalf of Poolbeg confirms a US$10 billion market opportunity for POLB 001 in Cancer Immunotherapy-Induced CRS as an orally delivered preventative therapy. Cancer immunotherapies have been approved in rare and orphan blood cancers and so the Company can see potential for POLB 001 in one or more of these cancer types. POLB 001 in cancer immunotherapy-induced CRS will be developed alongside Poolbeg's existing portfolio of assets including our influenza programme, AI drug discovery programmes and oral delivery of GLP-1 for obesity and other metabolic diseases.
Posted at 07/2/2024 23:27 by troutisout
50% of the share issue of POLB was owned by the shareholders of HVO, many sold their POLB shares many doubled down and bought more. I try and buy a bit of both every month to average in to a large holding, but some times when there is a disparity I favour the underdog and it seems to have worked up to now...
I am sure there may be a slight correlation to other pharma stocks, but not as closely aligned as these two are.
I have seen others mention profits from one flowing into the other on these BBs if others are thinking that then perhaps there is something to that?

Pink lines show when POLB got ahead of HVO and when it caught up, green lines when HVO went ahead of POLB. It's a pattern that has happened many times and so unlikely to be just pure coincidence.


free stock charts from uk.advfn.com
Posted at 07/2/2024 18:54 by troutisout
We have all seen the great rise in HVO over the last 7 months, starting with contract wins in late June and July, then the positive trading update at the end of July and of course, what was the start of Institutional buying.
Before that POLB mirrored HVO quite closely, deviating a little every now and then and then one or the other adjusting back.
POLB showed the way in late Summer/Autumn 2022 with HVO mirroring the moves several weeks later.
Then HVO leapt ahead of POLB in the late Summer/Autumn 2023, but the news of the Amryt team joining propelled POLB back up there again in November. As we went into the Christmas period and the New Year HVO has hit the rocket boosters with more contract wins and a really good TU. POLB has dithered and dropped slightly.
I don't think the relationship between the two has broken (although the II buying in HVO will have diluted the relationship where many of the holders of HVO also held POLB). So we wait to see if POLB catches up again, it certainly looks a few weeks behind but the correlation has been strong up to now....

POLB black, HVO Blue, HVO overlaid on POLB from the first day of POLB trading


free stock charts from uk.advfn.com
Posted at 05/1/2024 12:24 by sikhthetech
1gw,

"That usually sees a fair few announcements, so it's possible there's at least speculation that Poolbeg will be putting out something around that."


Does it? What announcements did Polb publish last year after the conference. Oh nothing.

You forgot to mention how much revenue they have? How much did Polb announce for fy2022?

NIL


Still trying to suck in punters based on your stories/suggestions, hoping they don't check.

Always best to check anything written by 1gw and his mates with multiple ids. A very long history of inventing stories to suck in punters, which don't come true. A very long list of shares which eventually crash.

Look at Trmr, Byot, rthm, Blnx, Stu, Nano etc etc each one down 80-90%...

Bar STU, I warned of the red flags on the others.



sikhthetech - 02 Mar 2023 - 11:35:06 - 2229 of 2667 Poolbeg Pharma - POLB
CF used to present good presentations did he?.

As of latest published results, Polb had ZERO revenues, yet £1.2m admin costs.

The access to HVO data is currently Free but Polb will start paying for it in 6 months time.

Mcap £52m with jam tomorrow.

Your Recent History

Delayed Upgrade Clock